Home Analyst Ratings Credit Suisse lifts Solid Biosciences rating to Neutral and price target...

Credit Suisse lifts Solid Biosciences [SLDB] rating to Neutral and price target to $7

Credit Suisse took its Solid Biosciences [SLDB] rating to the equivalent of Neutral from Underperform, and the price target to $7.0, in a research note dated 2021-01-08. That figure represents around a -17.45% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with SVB Leerink’s analysts downgrading the shares from “an Outperform” rating to “a Mkt perform” rating in a research note to investors issued in late July. Meanwhile, Evercore ISI had lowered its rating on SLDB to “an In-line” from the earlier “an Outperform”, in a research note produced for clients May 07, 2020. In addition, Evercore ISI launched coverage on October 11, 2019. The research firm rated SLDB “an Outperform”.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is Solid Biosciences Inc. [NASDAQ:SLDB] a Good Buy Right Now?

It should be noted that SLDB technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 88% Buy in the past month. Data from Solid Biosciences Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 4.4 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 2.0 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 3.53 million shares.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


SLDB Price Performance

On Wall Street, Solid Biosciences Inc. [NASDAQ:SLDB] finished Thursday’s session up 19.77% at $8.48. The stock went up to $8.555 at the same session while its lowest single day price was $7.099. In the last five days, it saw a rise of about 8.86%, Solid Biosciences Inc. shares gained by almost 11.87% since the beginning of the year. However, the share price has dropped to as low as 2.91% below its one year high. On 01/07/21, the company shares recorded $8.56, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $6.95. The company’s shares have inclined by 91.42% in the past year. The 50-day SMA achieved is $4.62 while the 200-day SMA is $3.25. Volume gained to 1.87 million from 0.85 million in the previous session.

SLDB Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 7.53 level, and in case of violation of this particular level, it will cause more drop to 6.59 level. On the upper level, 9.50 is still the key resistance. The stock may increase to the subsequent resistance at 8.99. The Relative Strength Index (RSI) pinned on the 14-day chart is 71.09, implying a overbought technical stance while the MACD stands at 0.35, meaning price will decrease in the next trading period. Percent R indicator moved to 2.78%, implying bullish price movement. Stochastic %K at 76.60% suggest selling the stock.

What is the short interest in Solid Biosciences Inc.?

Short interest in the Solid Biosciences Inc. stock has surged, increasing by 0.76 million shares to total 2.45 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 3.21 million, data from Yahoo Finance shows. The decrease of -31.02% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 3.87% of the overall float for the stock.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Solid Biosciences Inc.’s Biggest Shareholders: Who Owns Solid Biosciences Inc. [SLDB]?

Filings by Perceptive Advisors LLC showed that the firm now holds a total of 10,803,857 shares or roughly 17.87% of the outstanding SLDB shares. This means their shares have increased by 4,054,054 from the 10,803,857 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, RA Capital Management LP updated stake is worth $33,022,112. Details in the latest 13F filings reveal that Ecor1 Capital LLC acquired their 70.04% stake valued at $17,460,250 while BlackRock Fund Advisors cut theirs at $6,631,701. During the last quarter, Ecor1 Capital LLC raised 2,172,762 of its shares in Solid Biosciences Inc. while BlackRock Fund Advisors sold -78,206 shares. The Invus Public Equities Advisors LL’s holdings currently number 1,710,000 shares at $14500800.0. According to the firm’s last 13F report, Tavistock Life Sciences Co. shares in the company at filing stood at 1,531,872 shares, roughly $5,070,496.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Apple Inc. (AAPL) Stocks dip but future prospects for the company seem very positive

On Thursday, Apple shares (NASDAQ: AAPL) closed at $120.99 which is 3.5% lower. In the after-hours session, the price further declined by 0.2%.  The...

Tesla Inc. (TSLA): a Game of Thrones, Tweets and Bitcoin

Tesla Inc. (NASDAQ: TSLA) shares plunged by more than 8% when the market closed on Thursday. The news that most significantly impacted this plunge...

The Reasons Behind 30% Fall Of Tricida, Inc.’s (TCDA) Shares In Extended Trades

The drugmaker Tricida, Inc.’s (TCDA) shares experienced a fall of -29.62% in the trading after the ring of the bell on Thursday. The South...

Why Chromadex Corp. (CDXC) Remains A Gainer After Ring Of The Bell?

The biotechnology company ChromaDex Corporation (CDXC) continued the rally after ring of the bell on Thursday rising +18.68%. During the regular session price of...

ReTo Eco-Solutions Stock Drops Pre-Market Today: Why?

The manufacturer and distributor of construction material ReTo Eco-Solutions Inc. (NASDAQ: RETO) has been experiencing a fall of more than 10% in pre-market session...

What Took Gabelli Healthcare (GRX) Stock Down 18% In Pre-Market?

The Gabelli Healthcare & Wellness Trust (GRX) is sinking -18.33% in pre-market trading today following the announcement of a cash distribution by the organization...

What’s Hurting Tengasco Inc (TGC) Stock? Why Is It Down 26% Pre-Market?

Stock of oil and gas exploration firm Tengasco, Inc. (NYSE: TGC) is seeing a decline in pre-market trades today. Shares of the company were...

Apple Inc. (AAPL) Stocks dip but future prospects for the company seem very positive

On Thursday, Apple shares (NASDAQ: AAPL) closed at $120.99 which is 3.5% lower. In the after-hours session, the price further declined by 0.2%.  The...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.